RxDoctor Payments Data

Cory Lindenman, OD

Optometrist · Winfield, KSNPI 1871506071

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (56.1%), food and beverage and entertainment — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 57.0% of the total. Reporting peaked in 2019 at $2,112 and has fallen 89.7% since, to $218 in 2025. Among optometrist clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,540in general payments, 2019–2025

Across 61 payments — averaging $58.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
  • Biotissue Holdings Inc.$475
  • Coopervision Inc.$274
  • Alcon$241
  • Dompe US, Inc.$199
  • Genentech USA, Inc.$123
  • plus $211 from 5 others

What the payments were for

  • Travel & lodging$1,98656%
  • Food & beverage$1,53743%
  • Entertainment$160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,540 in reported general payments places this provider in the 90th percentile of 567 optometrist providers in Kansas.

See all optometrist providers in Kansas

Medicare billing

Part B allowed, 2024
$238,345
Medicare patients
773
Services billed
2,731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj24$782,640
RestasisCyclosporine15$15,927
XiidraLifitegrast18$12,040
Cyclosporine14$5,823
Cosopt PfDorzolamide/Timolol/Pf12$2,375
Travoprost19$1,939
Latanoprost181$1,698
Brimonidine Tartrate46$997
Prednisolone Acetate33$961
Timolol Maleate103$690
Dorzolamide Hcl35$520
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat17$151
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha14$146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$199$782,64024 claims
AbbVieRestasis$16$15,92715 claims
Bausch & Lomb Americas Inc.Xiidra$18$12,04018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 567 optometrist providers in Kansas.

Other optometrist in Winfield

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →